Dec 8 (Reuters) - Mirum Pharmaceuticals said on Monday it will acquire Bluejay Therapeutics in a deal worth up to $820 ...
Mirum inks 620M deal to acquire Bluejay Therapeutics, adding brelovitug, a phase 3 hepatitis delta drug, to its liver disease pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback